Brookfield Renewable Partners delivered an 8% increase in FFO in Q1-2024 and announced a long-term deal with Microsoft for renewable energy. BEP's valuation is now trading at about 16X AFFO or CAFD ...
Despite political and inflationary headwinds, I remain bullish on BEP, due to robust operating results and a strong growth outlook. In fact, even the ~24% return figure since my earlier piece on BEP ...
A randomized phase II trial of intensive induction chemotherapy (CBOP/BEP) and standard BEP in poor prognosis germ cell tumors (MRC TE23, CRUK 05/014, ISRCTN53643604). This is an ASCO Meeting Abstract ...
Earnings call Brookfield Renewable reported 10% YoY FFO per unit growth to $2.01 in 2025, with Q4 FFO up 14% YoY. The company deployed $8.9B in growth capital, commissioned 8 GW of new capacity, and ...
We used bleomycin, etoposide, cisplatin (BEP), the most effective regimen in the treatment of germ cell tumours (GCTs) and increased dose-density by using pegfilgrastim to shorten cycle length. Our ...
Brookfield Renewable Partners L.P. (TSX: BEP.UN; NYSE: BEP) (“BEP”) of its intention to renew its normal course issuer bids for its limited partnership units (“LP Units”) and Class A preferred limited ...
BROOKFIELD, News, July 16, 2020 (GLOBE NEWSWIRE) -- Brookfield Renewable Partners L.P. (“Brookfield Renewable” or “BEP”) (NYSE: BEP; TSX: BEP.UN) today announced that it has set July 27, 2020 as the ...
Patients were randomly assigned to receive either T-BEP or standard BEP. Patients assigned to the T-BEP group received paclitaxel 175 mg/m 2 in a 3-hour infusion. Patients who were administered T-BEP ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results